Showing 3871-3880 of 8905 results for "".
- New Agreement Opens Premier Networks to TeleVox Techhttps://practicaldermatology.com/news/televox-and-premier-inc-announce-national-patient-engagement-agreement/2476115/TeleVox has announced a national group purchasing agreement with Premier, Inc. effective September 1, 2025, permiting Premier members to access negotiated pricing and terms for TeleVox offerings, including Digital Front Door, Appointment Management, Digital Care P
- GLP-1 Users Drive Growth in Aesthetic Surgeryhttps://practicaldermatology.com/news/glp-1-users-drive-growth-in-aesthetic-surgery/2476140/Aesthetic surgery among patients with previous glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is increasing compared with postbariatric surgery patients, according to new research published in
- Switching Biologics for Psoriasis May Improve Outcomes Without Added Risk: Studyhttps://practicaldermatology.com/news/switching-biologics-for-psoriasis-may-improve-outcomes-without-added-risk-study/2476064/Plaque psoriasis patients who are unresponsive to initial biologics may derive benefit from switching to another drug class, according to a new meta-analysis of 24 randomized controlled trials (RCTs). The review looked at da
- Dr. Ted Rosen on JAK Inhibitors for Refractory Granulomatous and Autoimmune Dermatoseshttps://practicaldermatology.com/news/Dr-Ted-Rosen-JAK-Inhibitors-Refractory-Granulomatous-Autoimmune-Dermatoses/2476038/The role of JAK inhibitors in diseases characterized by chronic macrophage–T-cell interactions continues to grow, Theodore Rosen, MD, said at the DEF Essential Resource Meeting 2025 (DERM2025). The discussion focused on granuloma annulare (GA), sarcoidosis, lichen planus (LP), and lupus erythemat
- Study: Many May Avoid Cancer Treatment Due to Skin Side Effectshttps://practicaldermatology.com/news/study-one-third-may-avoid-cancer-treatment-due-to-skin-side-effects/2476010/A new pilot survey revealed that dermatologic side effects (DSEs) from anti-cancer therapies (ACTs) are widely misunderstood and could influence treatment decisions among patients in underserved communities. Researchers from th
- Deucravacitinib Plus Topical C/BD Effective in Moderate to Severe Psoriasis: Analysishttps://practicaldermatology.com/news/deucravacitinib-plus-topical-cbd-effective-in-moderate-to-severe-psoriasis-analysis/2476009/New research in the Journal of Drugs in Dermatology suggests that adding topical calcipotriene/betamethasone dipropionate (C/BD) foam to oral deucravacitinib therapy improves outcomes and quality of life in patients with moderate to severe chronic plaque p
- Data Show HS Tied to Elevated Depression, Anxiety Riskhttps://practicaldermatology.com/news/data-show-hs-tied-to-elevated-depression-anxiety-risk/2475943/Patients with hidradenitis suppurativa (HS) face elevated risk of developing new-onset depression and anxiety compared with the general population, according to findings from a population-based cohort. The analysis included 1
- 2025 ASDS Survey: 70% of Consumers Considering Cosmetic Procedureshttps://practicaldermatology.com/news/2025-asds-survey-70-of-consumers-considering-cosmetic-procedures/2475889/Seventy percent of Americans are considering a cosmetic dermatologic procedure, trusting board-certified dermatologists as top influencers in patient decision-making, according to the 2025 Consumer Survey on Cosmetic Dermatologic Procedures by the American Society
- Study: Emollient Use in Infancy Reduces AD Incidence by Age 2https://practicaldermatology.com/news/study-emollient-use-in-infancy-reduces-ad-incidence-by-age-2/2475883/Daily full-body emollient use beginning before 9 weeks of age significantly reduced the incidence of atopic dermatitis (AD) in a general infant population, according to new study results published in JAMA Dermatology.
- FDA Greenlights First Treatment for Chronic Hand Eczema in Adultshttps://practicaldermatology.com/news/fda-approves-first-treatment-for-chronic-hand-eczema-in-adults/2475816/The US Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream, making it the first and only treatment approved for adults with moderate-to-severe chronic hand eczema (CHE) who are unresponsive to topical corticosteroids or for those unsuitabl